CHLORPROMAZINE HYDROCHLORIDE

First approved in 1954

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H19ClN2S.ClH
Molecular Weight	355.325
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of CHLORPROMAZINE HYDROCHLORIDE

Structure Search

SMILES

Cl.CN(C)CCCN1C2=CC=CC=C2SC3=CC=C(Cl)C=C13

InChI

InChIKey=FBSMERQALIEGJT-UHFFFAOYSA-N

InChI=1S/C17H19ClN2S.ClH/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20;/h3-4,6-9,12H,5,10-11H2,1-2H3;1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C17H19ClN2S
Molecular Weight	318.864
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/pro/chlorpromazine.html | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display | https://www.drugbank.ca/drugs/DB00477

Chlorpromazine is a psychotropic agent indicated for the treatment of schizophrenia. It also exerts sedative and antiemetic activity. Chlorpromazine has actions at all levels of the central nervous system-primarily at subcortical levels-as well as on multiple organ systems. Chlorpromazine has strong antiadrenergic and weaker peripheral anticholinergic activity; ganglionic blocking action is relatively slight. It also possesses slight antihistaminic and antiserotonin activity. Chlorpromazine acts as an antagonist (blocking agent) on different postsysnaptic receptors -on dopaminergic-receptors (subtypes D1, D2, D3 and D4 - different antipsychotic properties on productive and unproductive symptoms), on serotonergic-receptors (5-HT1 and 5-HT2, with anxiolytic, antidepressive and antiaggressive properties as well as an attenuation of extrapypramidal side-effects, but also leading to weight gain, fall in blood pressure, sedation and ejaculation difficulties), on histaminergic-receptors (H1-receptors, sedation, antiemesis, vertigo, fall in blood pressure and weight gain), alpha1/alpha2-receptors (antisympathomimetic properties, lowering of blood pressure, reflex tachycardia, vertigo, sedation, hypersalivation and incontinence as well as sexual dysfunction, but may also attenuate pseudoparkinsonism - controversial) and finally on muscarinic (cholinergic) M1/M2-receptors (causing anticholinergic symptoms like dry mouth, blurred vision, obstipation, difficulty/inability to urinate, sinus tachycardia, ECG-changes and loss of memory, but the anticholinergic action may attenuate extrapyramidal side-effects). Additionally, Chlorpromazine is a weak presynaptic inhibitor of Dopamine reuptake, which may lead to (mild) antidepressive and antiparkinsonian effects. Chlorpromazine has being marketed under the trade names Thorazine and Largactil among others. Chlorpromazine is used for treating certain mental or mood disorders (eg, schizophrenia), the manic phase of manic-depressive disorder, anxiety and restlessness before surgery, the blood disease porphyria, severe behavioral and conduct disorders in children, nausea and vomiting, and severe hiccups.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 311 Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16867246 \| https://www.ncbi.nlm.nih.gov/pubmed/25557493 \| https://www.ncbi.nlm.nih.gov/pubmed/23919353 \| https://www.ncbi.nlm.nih.gov/pubmed/7918347	Antagonist 2849	1.0 nM [IC50]
Serotonin 2a (5-HT2a) receptor 237 Target ID: CHEMBL224 Sources: https://www.drugbank.ca/drugs/DB00477 \| https://www.ncbi.nlm.nih.gov/pubmed/23919353	Antagonist 2849	3.4 nM [IC50]
Dopamine D1 receptor 106 Target ID: CHEMBL2056 Sources: https://www.drugbank.ca/drugs/DB00477 \| https://www.ncbi.nlm.nih.gov/pubmed/7918347	Antagonist 2849	56.0 nM [Ki]
Histamine H1 receptor 316 Target ID: CHEMBL231 Sources: https://www.drugbank.ca/drugs/DB00477 \| https://www.ncbi.nlm.nih.gov/pubmed/23919353	Antagonist 2849	12.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Schizophrenia 305 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8583	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date 1957
Manic-depressive disease 9 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8583	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date 1957
Acute intermittent porphyria 7 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8583	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date 1957
Nausea and vomiting 19 Sources: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=c63d6612-3fd2-44dd-a5c7-a093766b91f2&type=display	Primary	Approved 8583	THORAZINE Approved Use For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Launch Date 1957

C_max

Value	Dose	Analyte	Population
4.31 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
37.9 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
135 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
27.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
81.8 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
247 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
11.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	10 mg single, intravenous dose: 10 mg route of administration: Intravenous experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
5.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
9.52 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	50 mg single, oral dose: 50 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
11.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8157044	100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered:	CHLORPROMAZINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
10% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4399487	unknown, unknown		CHLORPROMAZINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
75 mg 1 times / day multiple, intravenous Highest studied dose Dose: 75 mg, 1 times / day Route: intravenous Route: multiple Dose: 75 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/30558470	unhealthy, 52 years (range: 36.5-65.6 years) Health Status: unhealthy Age Group: 52 years (range: 36.5-65.6 years) Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/30558470	Sources: https://pubmed.ncbi.nlm.nih.gov/30558470
100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512	unhealthy, Elderly Patients Health Status: unhealthy Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512
25 mg 1 times / day multiple, intramuscular Dose: 25 mg, 1 times / day Route: intramuscular Route: multiple Dose: 25 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0	unhealthy, Elderly Patients Health Status: unhealthy Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0	Other AEs: Adverse event... Other AEs: Adverse event (grade 5) Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0

AEs

AE	Significance	Dose	Population
Adverse event	grade 5	100 mg 1 times / day multiple, oral Recommended Dose: 100 mg, 1 times / day Route: oral Route: multiple Dose: 100 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512	unhealthy, Elderly Patients Health Status: unhealthy Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=432cd4ca-c728-48ff-beec-2485f5e02512
Adverse event	grade 5	25 mg 1 times / day multiple, intramuscular Dose: 25 mg, 1 times / day Route: intramuscular Route: multiple Dose: 25 mg, 1 times / day Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0	unhealthy, Elderly Patients Health Status: unhealthy Age Group: Elderly Patients Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0f1fcfd-8863-4032-bf80-185df60a4ba0

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946		inhibitor 2507 substrate 1388	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2E1 1060 P-gp 1741 BCRP 910 UGT2B10 31 OCT2 779 OATP1A2 43	CYP1A2 1197 P-gp 2052	CYP2B 32 CYP3A 142

Drug as perpetrator

Target	Modality	Activity
BCRP 985	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2637613/	mild [IC50 52.2 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/15135088/	weak [IC50 1000 uM]
OATP1A2 43	inhibitor 4027 Sources: https://jpet.aspetjournals.org/content/352/3/552?cited-by=yes&legid=jpet%3B352/3/552	yes [IC50 12 uM]
OCT2 782	inhibitor 4027 Sources: https://pubmed.ncbi.nlm.nih.gov/19002438/	yes [IC50 14 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586484/	yes [IC50 20 uM]
P-gp 1932	inhibitor 4027 Sources: https://link.springer.com/article/10.1007/s00213-006-0437-9?shared-article-renderer	yes [IC50 5.8 uM]
UGT2B10 33	inhibitor 4027 Sources: https://dmd.aspetjournals.org/content/dmd/44/3/378.full.pdf#page=6 Page: 6.0	yes [IC50 79 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3586484/	yes [IC50 9.5 uM]
CYP2B 41	inducer 1966 Sources: https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0773.1999.tb02018.x	yes
CYP3A 317	inducer 1966 Sources: https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1600-0773.1999.tb02018.x	yes

Drug as victim

Target	Modality	Activity
CYP1A2 1197	substrate 4014 Sources: https://www.longdom.org/open-access/cyp450-and-its-implications-in-the-clinical-use-of-antipsychotic-drugs-2161-1459-1000176.pdf Page: 4.0	yes
CYP2D6 1388	substrate 4014 Sources: https://www.sciencedirect.com/science/article/pii/S1110863017300228	yes
CYP3A4 1946	substrate 4014 Sources: https://www.longdom.org/open-access/cyp450-and-its-implications-in-the-clinical-use-of-antipsychotic-drugs-2161-1459-1000176.pdf Page: 4.0	yes
P-gp 2052	substrate 4014 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913737/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1573882/

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:3647	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:3647
ChemicalBook	CB5547531	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB5547531
eMolecules	730270	https://www.emolecules.com/cgi-bin/more?vid=730270
MolPort	MolPort-001-727-953	https://www.molport.com/shop/molecule-link/MolPort-001-727-953
ZINC	ZINC000000044027	http://zinc15.docking.org/substances/ZINC000000044027

PubMed

Title	Date	PubMed
Deanol in the treatment of tardive dyskinesia.	1975 Aug	1147074
Effects of chlorpromazine on bilirubin metabolism and biliary secretion in the rat.	1975 Oct	1175890
Altered pilocarpine- or chlorpromazine-induced catalepsy after long-term treatment with cholinergic drugs.	1979 Nov	119254
A case of phenobarbital exacerbation of a preexisting maladaptive behavior partially suppressed by chlorpromazine and misinterpreted as chlorpromazine efficacy.	1992	1509179
Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification.	1992	1350058
An unusual cause of convulsions in a newborn infant.	1992 Dec	1473547
Pharmacological characteristics of alpha 2-adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning.	1992 Jul	1353247
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs.	1992 Sep	1416885
Ca(2+)-calmodulin antagonist chlorpromazine and poly(ADP-ribose) polymerase modulators 4-aminobenzamide and nicotinamide influence hepatic expression of BCL-XL and P53 and protect against acetaminophen-induced programmed and unprogrammed cell death in mice.	2001 Aug 1	11461765
Chlorpromazine-induced cholestatic liver disease with ductopenia.	2001 Jul	11669021
Antipsychotic-induced extrapyramidal syndromes. Risperidone compared with low- and high-potency conventional antipsychotic drugs.	2001 Jul	11549212
Role of flavonoids in controlling the phototoxicity of Hypericum perforatum extracts.	2001 Jul	11515722
Combination of benzo[a]phenothiazines with acyclovir against herpes simplex virus.	2001 Jul	11463529
Torsades de pointes associated with chlorpromazine: case report and review of associated ventricular arrhythmias.	2001 Jul	11444585
Iatrogenic cardiopulmonary arrest during pediatric sedation with meperidine, promethazine, and chlorpromazine.	2001 Oct	11673713
Oral contraceptives increase the plasma concentrations of chlorpromazine.	2001 Oct	11591904
Enhanced dendritic cell-driven proliferation and anti-HIV activity of CD8(+) T cells by a new phenothiazine derivative, aminoperazine.	2001 Sep 1	11509641
[Ultraviolet spectrophotometric determination of psychotropic drug mixtures].	2002	12474759
[Poisonings with psychotropic drug mixtures: analysis using the thin-layer chromatography method].	2002	12474689
Specific and overlapping functions of the nuclear hormone receptors CAR and PXR in xenobiotic response.	2002	12049174
[Creutzfeldt-Jakob disease: diagnosis, incidence, prevention and treatment].	2002 Apr 20	11998351
Effects of chlorpromazine, pentoxifylline and dexamethasone on mRNA expression of lipopolysaccharide-induced inflammatory cytokines in bovine peripheral blood mononuclear cells.	2002 Aug	12237520
[Models of drug treatment in the attention deficit disorder with hyperactivity].	2002 Feb	12447798
Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms.	2002 May	12010767
Toxicity and carcinogenicity studies of chlorpromazine hydrochloride and p-cresidine in the p53 heterozygous mouse model.	2002 Nov-Dec	12512871
[The effect of microwaves on the bioelectric brain activity].	2002 Sep-Oct	12449823
Scopolamine-induced convulsions in fasted mice after food intake: determination of blood glucose levels, [3H]glutamate binding kinetics and antidopaminergic drug effects.	2003 Feb	12623218
Acute massive pulmonary thromboembolism associated with risperidone and conventional phenothiazines.	2003 Jan	12520151
[Reversal of multidrug resistance in leukemic cell line K562/AO2 by chlordelazine in vitro].	2003 Jul	14746680
The antipsychotic drug chlorpromazine inhibits HERG potassium channels.	2003 Jun	12788816
Examination of the functional activity of P-glycoprotein in the rat placental barrier using rhodamine 123.	2003 Jun	12626638
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.	2003 Mar	12629531
Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis.	2003 Mar	12604522
Copper-stimulated endocytosis and degradation of the human copper transporter, hCtr1.	2003 Mar 14	12501239
Application of the CFU-GM assay to predict acute drug-induced neutropenia: an international blind trial to validate a prediction model for the maximum tolerated dose (MTD) of myelosuppressive xenobiotics.	2003 Oct	12883091
Mechanism of C2-toxin inhibition by fluphenazine and related compounds: investigation of their binding kinetics to the C2II-channel using the current noise analysis.	2003 Oct 24	14556742
UVA activated 8-MOP and chlorpromazine inhibit release of TNF-alpha by post-transcriptional regulation.	2004 Apr	15052360
Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors.	2004 Apr 15	15135088
Smoking impact on CYP1A2 activity in a group of patients with schizophrenia.	2004 Jan	14659985
Spasmodic dysphonia, a rare form of tardive dystonia, induced by low-dose risperidone?	2004 Mar	14961937
Drug-induced liver injury.	2004 Mar 1	14986274
Block of HERG human K(+) channel and IKr of guinea pig cardiomyocytes by chlorpromazine.	2004 May	15071359
Antipsychotics increase microtubule-associated protein 2 mRNA but not spinophilin mRNA in rat hippocampus and cortex.	2004 May 1	15079866
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.	2004 Oct	15083255
Oral terbutaline in the management of pharmacologically induced prolonged erection.	2004 Oct	14999218
The phenothiazine drugs inhibit hERG potassium channels.	2005	16051556
A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system.	2005 Feb	15342952
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates.	2005 Nov	16251329
Retinoid-mediated stimulation of steroid sulfatase activity in myeloid leukemic cell lines requires RARalpha and RXR and involves the phosphoinositide 3-kinase and ERK-MAP kinase pathways.	2006 Feb 1	16178010
Frequency of high-risk use of QT-prolonging medications.	2006 Jun	16178046

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Psychosis HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day Usual Adult Dose for Schizophrenia HOSPITALIZED PATIENTS: Acute Schizophrenia/Manic States: Oral: -Usual dose: 500 mg/day orally -Maximum dose: 2000 mg/day Parenteral: -Usual dose: 25 mg IM once, with a subsequent 25 to 50 mg injection in 1 hour if necessary -Maintenance dose: 400 mg IM every 4 to 6 hours until the patient is controlled Prompt Control of Severe Symptoms: Oral: -Usual dose: After an initial IM dose, 25 to 50 mg orally 3 times a day Parenteral: -Usual dose: 25 mg IV once, repeated in 1 hour if necessary Less Acutely Disturbed: Oral: -Initial dose: 25 mg orally 3 times a day -Usual dose: 400 mg/day

Route of Administration: Other

In Vitro Use Guide

Chlorpromazine inhibited the serotonin2-mediated excitation of the interneurons of rat piriform cortex with an IC50 of 14 uM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:50:16 GMT 2025` Edited by `admin` on `Mon Mar 31 17:50:16 GMT 2025`
Record UNII	9WP59609J6
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

CHLORPROMAZINE HYDROCHLORIDE

Common Name

English

PROMAPAR

Preferred Name

English

CHLORPROMAZINE HYDROCHLORIDE [JAN]

Common Name

English

10-(3-DIMETHYLAMINOPROPYL)-2-CHLOROPHENOTHIAZINE MONOHYDROCHLORIDE

Systematic Name

English

CHLORPROMAZINE HYDROCHLORIDE [VANDF]

Common Name

English

NCI-C05210

Common Name

English

CHLORPROMAZINE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

CHLORPROMAZINE HYDROCHLORIDE [USP-RS]

Common Name

English

10H-PHENOTHIAZINE-10-PROPANAMINE, 2-CHLORO-N,N-DIMETHYL-, MONOHYDROCHLORIDE

Common Name

English

Chlorpromazine hydrochloride [WHO-DD]

Common Name

English

CHLORPROMAZINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

2-Chloro-10-[3-(dimethylamino)propyl]phenothiazine monohydrochloride

Systematic Name

English

CHLORPROMAZINI HYDROCHLORIDUM [WHO-IP LATIN]

Common Name

English

CHLORPROMAZINE HCL

Common Name

English

CHLORPROMAZINE HYDROCHLORIDE [MART.]

Common Name

English

CHLORPROMAZINE HYDROCHLORIDE [EP IMPURITY]

Common Name

English

CHLORPROMAZINE HYDROCHLORIDE [GREEN BOOK]

Common Name

English

KLORPROMAN

Common Name

English

NORCOZINE

Common Name

English

SONAZINE

Brand Name

English

CHLORPROMAZINE HYDROCHLORIDE [WHO-IP]

Common Name

English

CHLORPROMAZINE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

CHLORPROMAZINE HYDROCHLORIDE [MI]

Common Name

English

MARAZINE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C740